← Leaderboards
Kendall Moseley
Johns Hopkins University
$1,661,432
Attributed
$1,661,432
Total exposure
3
Grants
3
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants. They are the sole PI on all grants (the two match).
Funding over time
peak $370.5K · FY2011–19$500K$375K$250K$125K$0
'11
'12
'13
'14
'15
'16
'17
'18
'19
Funding mix
By agency
NIH$1,661,432 · 3
By mechanism
K23$923,610 · 1
R21$575,822 · 1
R03$162,000 · 1
Top collaborators
No co-investigators on record.
Most similar at Johns Hopkins University
Same institution · by research overlap
- Michael Mingzhao Xing$6,781,300
- David Sidransky$59,922,938
- Patrizio Caturegli$4,739,009
- Stanley R Hamilton$26,840,413
- Ruth E. Stark$6,150,743
Others in their field
Top investigators on “Fracture”
- Steven R Cummings · University Of California San Francisco$61,819,247
- Eric S. Orwoll · Oregon Health And Science University$51,015,480
- Douglas P. Kiel · Hebrew Rehabilitation Center For Aged$44,673,806
- Peter J. Snyder · University Of Pennsylvania$35,330,958
- Jay Steven Magaziner · University Of Maryland Baltimore$31,737,082
- Kathryn M Anastos · Montefiore Medical Center (Bronx, Ny)$27,163,632
Research focus
FractureOsteoblastsSkeletalFutureBoneDisabilityMorbidity - Disease RateSerumBone DensityFrailtyPreventBone QualityHip Region StructureHip FracturesGlucose ToleranceAgingImpaired Glucose ToleranceOsteogenesisFunctional DisorderCatalystBiochemicalNon-Insulin-Dependent Diabetes MellitusMetabolicDiabetes Mellitus
Grant awards (9)
Skeletal survivorship and immune therapy: The effects of nivolumab on bone metabolism in renal cell carcinoma$370,511
R21 · FY2019 · AR · contact PI
Skeletal survivorship and immune therapy: The effects of nivolumab on bone metabolism in renal cell carcinoma$205,311
R21 · FY2018 · AR · contact PI
Defining and demystifying bone quality in type 2 diabetes mellitus$185,706
K23 · FY2016 · DK · contact PI
Defining and demystifying bone quality in type 2 diabetes mellitus$181,416
K23 · FY2015 · DK · contact PI
Defining and demystifying bone quality in type 2 diabetes mellitus$185,706
K23 · FY2014 · DK · contact PI
Defining and demystifying bone quality in type 2 diabetes mellitus$185,706
K23 · FY2013 · DK · contact PI
Defining and demystifying bone quality in type 2 diabetes mellitus$185,076
K23 · FY2012 · DK · contact PI
Glycemic derangement and osteogenic cells:A model of Premature skeletal aging$81,000
R03 · FY2012 · AG · contact PI
Glycemic derangement and osteogenic cells:A model of Premature skeletal aging$81,000
R03 · FY2011 · AG · contact PI